Compare Baker Hughes Co (BKR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Inovio Pharmaceuticals Inc — how do they compare? Baker Hughes Co trades at $64.27 (market cap $64.34B), while Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M). The key difference: Baker Hughes Co is far larger — about 819.1× Inovio Pharmaceuticals Inc's market cap, and Baker Hughes Co pays a 1.42% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BKR | INO | |
|---|---|---|
Market Cap | $64.34B | $78.55M |
Sector | Energy | Health |
52-Week High | $69.67 | $2.87 |
52-Week Low | $42.51 | $0.66 |
Enterprise Value | $64.86B | $49.56M |
Dividend Yield | 1.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.69, up 0.97% today, with strong technical and fundamental momentum. The stock shows bullish moving averages and has beaten earnings estimates for the last three quarters. Recent news includes major contracts for subsea systems and LNG technology, supporting revenue growth. Analyst consensus is strongly positive with a $73.25 price target, indicating ~13% upside from current levels.
Outlook remains favorable driven by energy infrastructure demand and operational execution, though risks include oil price volatility and integration challenges from the Chart acquisition. The stock offers growth potential with solid cash flow and margin expansion, but investors should monitor debt levels and global energy spending trends.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
